Ankara Training and Research Hospital, Endocrinology and Metabolism Diseases, Ankara, Turkey.
Hacettepe University Hospital, Pediatric Cardiology, Ankara, Turkey.
Endocr Metab Immune Disord Drug Targets. 2024;24(10):1237-1239. doi: 10.2174/0118715303252109231023115112.
The safety of glucagon-like peptide-1 receptor agonists in pregnancy is under investigation. In this report, we want to share the results of a patient with polycystic ovary syndrome who applied to our outpatient clinic for diabetes and had two unplanned pregnancies following the initiation of exenatide for obesity treatment.
A 40-year-old woman with diabetes was admitted to the endocrinology outpatient clinic. On physical examination, the body mass index was over 35 kg/m ², therefore, exenatide treatment was started. Four weeks later, she came to suspicion of pregnancy, and obstetric ultrasound revealed a fetus at 17 weeks of gestation. Exenatide was interrupted. At 37 weeks of gestation, she gave birth to a female baby with atrial septal defect. The baby was followed with echocardiography annually until spontaneous closure of ASD when she was three years old. Two years later, the patient consulted us again for weight gain. Exenatide was prescribed again. After 5 months, an abdominal ultrasound revealed a fatty liver and detected a pregnancy compatible with 13 weeks of gestation. Two siblings are healthy now, 7 and 5 years old, respectively.
This report contributes to our knowledge of fetal exposure to exenatide. Large-scale randomized studies are needed for its safe use in pregnancy.
胰高血糖素样肽-1 受体激动剂在妊娠中的安全性正在研究中。在本报告中，我们想分享一位多囊卵巢综合征患者的结果，该患者因肥胖接受艾塞那肽治疗后，意外怀孕两次，并来到我们的门诊就诊糖尿病。
一位 40 岁的糖尿病女性患者被收入内分泌科门诊。体格检查时，体重指数超过 35 kg/m ² ，因此开始使用艾塞那肽治疗。四周后，她怀疑自己怀孕了，产科超声显示胎儿妊娠 17 周。艾塞那肽被中断。妊娠 37 周时，她生下一名患有房间隔缺损的女婴。婴儿每年进行超声心动图随访，直到 3 岁时 ASD 自然闭合。两年后，患者因体重增加再次就诊。再次给她开了艾塞那肽。5 个月后，腹部超声显示脂肪肝，并检测到与妊娠 13 周相符的胎儿。现在，两个兄弟姐妹分别是 7 岁和 5 岁，都很健康。
本报告有助于我们了解胎儿暴露于艾塞那肽的情况。需要进行大规模的随机研究以确保其在妊娠中的安全使用。
